Clinical trials: T-cell Non-Hodgkin Lymphoma
Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.
- Trial name
- NCT07730515
- Testing
- XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Evopoint Biosciences Inc.
B-NHL, B-Non Hodgkin Lymphoma
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured.
- Conditions
- B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05442515
- Testing
- CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
This is a phase I, open-label, single-arm, multicenter study to assess the safety and efficacy of JWCAR029 in adult primary refractory DLBCL subjects in China
- Trial name
- NCT04812691
- Testing
- JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
B-cell Lymphoma
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
- Trial name
- CARMA-01 (NCT06002659)
- Testing
- CAR20(NAP)-T, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Sweden
- Volunteers
- 18 people
- Sponsor
- Uppsala University
T Lymphoblastic Leukemia/Lymphoma
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target.
- Trial name
- NCT05620680
- Testing
- CD7 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Cardiac Toxicity, Leukemia
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cardiac Toxicity, Leukemia, Lymphoma
- Trial name
- T-Cell #4 (NCT01230983)
- Testing
- asparaginase, cytarabine, dexrazoxane hydrochloride
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00290641
- Testing
- filgrastim, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Pruritus
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study
Mycosis Fungoides (MF) is a rare malignancy in the United States. It is the most common form of cutaneous T-cell lymphoma (CTCL). Sézary syndrome (SS) is the most severe and leukemic form of CTCL.
- Trial name
- NCT01801670
- Testing
- Biopsy, Blood
- Where
- United States
- Sponsor
- Boston University
Lymphoma, Extranodal NK-T-Cell
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F- FDG PET/CT and predict disease progression during chemotherapy or survival in…
- Trial name
- NCT03051542
- Testing
- 18F-FDG PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Sezary Syndrome, Ichthyosis, Lamellar
Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
Autosomal recessive congenital ichthyoses (ARCI) are monogenic diseases of cornification that correspond to a diffuse abnormality (affecting the entire integument) of epidermal differentiation and therefore of the skin barrier.
- Trial name
- NIPALYMPHO (NCT07477769)
- Testing
- blood sampling
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peripheral T-cell Lymphoma
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
This is a prospective, single arm, multicenter, dose-escalation clinical study to evaluate the safety and efficacy of CMOEP in patients with untreated Peripheral T-cell Lymphoma.
- Trial name
- NCT05458180
- Testing
- Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
B-cell Non-Hodgkin's Lymphoma
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.
- Trial name
- NCT04655677
- Testing
- Prizloncabtagene Autoleucel
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
This phase II trial studies how well onalespib works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previous treatment (refractory) or…
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT02572453
- Testing
- Onalespib
- Where
- 19 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Extranodal Natural Killer/T-cell Lymphoma
A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-up was terminated in 4 years.
- Trial name
- NCT05343377
- Testing
- circulate free methylated EBV DNA
- Where
- China
- Volunteers
- 72 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Diffuse Large B-Cell Lymphoma, B-Cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07881211
- Testing
- BG-T0050
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Peripheral T-cell Lymphoma
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
- Trial name
- Sincerely20 (NCT04512534)
- Testing
- PD-1 antibody+ HDAC inhibitor
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Fudan University
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Background: Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers.
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT01087333
- Where
- United States
- Volunteers
- 1,263 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Follicular, Lymphoma, Mantle-Cell
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- NCT04911478
- Testing
- ADI-001
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Adicet Therapeutics
Peripheral T-cell Lymphoma
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.
- Trial name
- NCT04480125
- Testing
- Azacitidine, Chidamide
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.